Phase II Vanguards Visualizer

A structured view of Phase II clinical trials led by emerging pharmaceutical and research organizations.

Phase II Vanguards Visualizer

A structured view of Phase II clinical trials led by emerging pharmaceutical and research organizations.
Cyntegrity logo – Risk-Based Quality Management Solutions

Understanding the Phase II Landscape

Phase II Vanguards is an interactive visualizer designed to help professionals understand who is advancing investigational therapies during the most uncertain stage of clinical development. It brings together trial, sponsor, and disease-level information into a single, interpretable view.

 

The visualizer exists to support learning and informed interpretation of Phase II activity—where early clinical promise is tested and many programs either progress or stop. By focusing on smaller and independent organizations, it highlights parts of the clinical research ecosystem that are often less visible but strategically important.

What You Can Explore With the Visualizer

Key ways the visualizer supports understanding of Phase II clinical trial activity:

Explore emerging Phase II sponsors

Gain visibility into companies, institutions, and research groups conducting Phase II studies outside the largest pharmaceutical organizations. This helps clarify who is driving development activity at this critical stage.

Understand disease and therapeutic focus

See how Phase II trials are distributed across therapeutic areas and indications. The visual structure makes it easier to recognize areas of concentration and emerging research themes.

Track trial progress and status

Review how studies are progressing, where they are located, and their current status. This supports a more grounded understanding of development momentum across the Phase II landscape.

About the Visual Approach

The Phase II Vanguards visualizer is based on structured data extracted from ClinicalTrials.gov, covering Phase II studies conducted between 2021 and 2023. Trials are filtered to include sponsors not affiliated with the top 100 pharmaceutical companies, allowing for focused analysis of independent and smaller-scale development efforts. The visual design emphasizes comparison, context, and pattern recognition rather than exhaustive detail.

 

Curious how Phase II activity is evolving across sponsors and indications?

Use the visualizer to explore relationships, trends, and trial characteristics at your own pace.

Part of the eyesON Interactive Visualizer Series

The eyesON series is Cyntegrity’s collection of interactive data visualizers created to support understanding through transparent, well-structured data exploration. These tools are developed as learning resources, making complex datasets more accessible without oversimplifying them.

 

Through the eyesON series, Cyntegrity shares its data analytics expertise and regulatory knowledge with the broader research community. Each visualizer transforms dense guidance and datasets into meaningful visual narratives that support learning, cross-functional dialogue, and practical understanding. Explore More Interactive Visualizers…

Explore Our Visualizer

A structured view of Phase II clinical trials led by emerging pharmaceutical and research organizations.

Stay Informed with Us

Risk-based quality management in 2026

Risk-based quality management in 2026: how ICH E6(R3) defines RBQM, where practice diverges, and what regulators now expect in clinical trials....
Diagram illustrating the FDA Total Product Lifecycle (TPLC) management approach for AI and machine learning devices, showing a continuous cycle of design, validation, submission, monitoring, and update.

FDA AI Guidance 2025 Interactive Visualizer

Explore how FDA’s 2025 AI guidance shapes lifecycle oversight for AI-enabled medical software through interactive regulatory scenarios....

Media Inquiries

Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.